NCT06900166View on ClinicalTrials.gov

Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

April 1, 2029

Study Completion Date

April 30, 2029

Conditions
Chronic Hepatitis B
Interventions
DRUG

PegIFN alfa-2b

180 μg/ 0.5 ml ,hypodermic injection once a week

DRUG

PegIFN alfa-2b and NUC

180 μg/ 0.5 ml ,hypodermic injection once a week, NUC drugs should be used according to the instructions of each drug

Trial Locations (1)

200040

Huashan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Huashan Hospital

OTHER